Has Arthur Topoulos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $36,144 in general payments to Arthur Topoulos, MD across 220 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arthur Topoulos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arthur Topoulos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arthur Topoulos, MD

Nuclear Cardiology · Philadelphia, PANPI 1952331944

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $24,684 of the $36,144 with a category attached, or 68.3%. Medtronic accounts for 69.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $26,806 and has fallen 95.0% since, to $1,351 in 2025.

$36,144in general payments, 2019–2025

Across 220 payments — averaging $164.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$25K
Bard Peripheral Vascular, Inc.$2K
Inari Medical, Inc.$1K
W. L. Gore & Associates, Inc.$1K
Cook Medical LLC$1K
Silk Road Medical, Inc.$1K
plus $4K from 19 others

$132,556in research payments, 2019–2025

Across 299 payments — averaging $443.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bayer$67K
Novo Nordisk AS$61K
Shockwave Medical, Inc$5K

What the payments were for

Royalty or licence$24,68468%
Travel & lodging$1,0573%
Food & beverage$9,75627%
Other$6482%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	16	$25,171
Bard Peripheral Vascular, Inc.	26	$2,043
Inari Medical, Inc.	7	$1,301
W. L. Gore & Associates, Inc.	33	$1,215
Cook Medical LLC	65	$1,184
Silk Road Medical, Inc.	10	$1,168
Veryan Medical Incorporated	3	$821
Cashflow Solutions, LLC	2	$661
Surmodics, Inc.	6	$624
Philips North America LLC	10	$552
Shockwave Medical, Inc	19	$381
Abbott	2	$160
Cordis US CORP.	4	$128
Siemens Medical Solutions USA, Inc.	2	$111
Biocompatibles, Inc.	1	$110
Edwards Lifesciences	1	$109
Boston Scientific	4	$89
Imperative Care, Inc	1	$64
Atricure, Inc.	1	$58
Janssen Scientific Affairs, LLC	1	$53
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$35
BD	1	$31
Inspire Medical Systems, Inc.	1	$28
Cardiva Medical, Inc.	1	$25
Cardiovascular Systems Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$284,858

Medicare patients

1,185

Services billed

2,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XareltoRivaroxaban	46	$54,254
EliquisApixaban	24	$18,999
Repatha SureclickEvolocumab	22	$11,481
Cilostazol	34	$668
Losartan Potassium	22	$386
ClopidogrelClopidogrel Bisulfate	32	$321
Rosuvastatin Calcium	21	$307
Ammonium Lactate	12	$243
Lisinopril	17	$222
Furosemide	28	$138

Paid to pharmacies, not to this prescriber.

Other nuclear cardiology in Philadelphia

Paco BravoPhiladelphia$1K
Ross ZimmerPhiladelphia$822
David SchwartzPhiladelphia$237
Neil LevinPhiladelphia$177
Harvey WaxmanPhiladelphia$20
Prem SomanPittsburgh$39K
Leroy MoorePittsburgh$3K
Rina Gandhi-KulkarniPittsburgh$2K
John RehderPittsburgh$324
William FollansbeePittsburgh$58

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →